He's quoting an article published on the Forbes website yesterday, albeit without attribution. Pickens did not pick the companies listed.
Howdy, jet. Been keeping a low profile, just sitting on positions. Let the last of my TSO and VLO shares go for the summer yesterday. No other refining positions currently. Stopped by looking for ideas to put the funds to work and noticed the message board seems to have returned to civility. Any ideas, besides cautioning this may be the year refiners don't retreat for the summer?
Breakthrough? That's what we thought about Stimuvax ... er, excuse me, Tecemotide ... five years ago. What is it this time?
I was following until you called ONTY a gem. ONTY still is a lump of coal waiting for Superman to squeeze it into a diamond, at least for those of us from the Stimuvax days.
'Those who cannot remember the past are condemned to repeat it.' (George Santayana). Kirkman's still is in the saddle, and remind me how long it has been since ONTY (back to Biomira days) has commercialized a product. Would not be surprised if ASCO presentation is not much more than a reiteration of ONT-380 results reported in December, like Kirkman did many times with Stimuvax.
$327M doesn't seem like much, but no telling how the market reacts to yet another prospect of a Greek default. History and current developments are on dfscorner's side from a trading perspective. Sometimes the market seems to be looking for an excuse. Watching for a possible Monday morning foray into SH, VXX, TLT or TLH myself, if the stampede is not already underway.
Can't answer for vlono.1fan, but Blake Fernandez at Scotia Howard Weil publishes a "Weekly Refining Indicators Report" that captures a whole lot of data related to US petroleum refining. You can just search what I included in quotation marks to find the latest report.
OPEC trying to put the damper on persistent strength in shale crude production. Didn't account for the best shale producers' ability to cut costs and increase efficiency.
The index reconstitution is not effective until June 26. The reduction in CTSO's market cap since March is closer to 60% and may have cost inclusion in the Russell 3000. The current market cap at $152M still is within the range of $30M - $884M for the 1633 companies included in the Micro-Cap index. Just FYI, the weighted average market cap for the index is $419M and the median $219M, so it would seem CTSO has a plenty of company in the low end of the range and, barring disastrous developments, would not appear to be in danger of being dropped at the next reconstitution.
The only one I could find in a cursory search was Blackrock's ETF mister_luckee mentioned in his post below. Perusing that fund's health care sector holdings in CTSO's current share price range, the fund may purchase only 50k -100k shares.
The proxy statement also indicates the additional shares could be used to consummate a merger or acquisition as well as to serve as a poison pill. Didn't Wilder say something about having freedom to do whatever it takes to turn around XCO?
Wow, I suspected something like this when the bottom fell out of the share price. Critical loss, Di Russo was the linchpin for all clinical trials. Says he has been at Pfizer since May. CTSO owed us an 8-K within four business days.